Approved Email vs RTE: When to Use Each Channel

Email remains one of the highest-ROI channels in pharmaceutical marketing, but not all pharma email is created equal. The two primary email channels, marketer-sent Approved Email and rep-triggered email (RTE), operate under fundamentally different workflows, performance dynamics, and strategic use cases. Understanding when to deploy each, and more importantly how to combine them for maximum impact, is a critical capability for omnichannel marketing teams.

Too many pharmaceutical brands treat Approved Email and RTE as interchangeable or, worse, as competitors for the same budget. In reality, they serve complementary roles in the HCP engagement ecosystem. Approved Email excels at broad reach, consistent messaging, and automated nurturing at scale. RTE excels at personal relevance, contextual timing, and leveraging the rep-HCP relationship. The brands that achieve the best email channel performance are those that deploy both strategically, using each for what it does best.

Defining the Two Channels

Approved Email (Marketer-Sent)

Approved Email is email sent from the brand's marketing operations team through an MLR-reviewed (Medical, Legal, Regulatory) template. The marketing team controls the send list, timing, content, and frequency. Sends are executed through a platform like Veeva Vault Promomats or a marketing automation tool integrated with Veeva CRM. The sender address typically appears as the brand name or a generic brand email address.

Key characteristics:

• Centralized control by the marketing operations team
• Content is MLR-reviewed and approved before deployment
• Send lists are defined by the marketing team based on segmentation criteria
• Timing is determined by campaign calendar and automated triggers
• Volume can scale to tens of thousands of HCPs per send
• Compliance is managed centrally through the approval workflow

Rep-Triggered Email (RTE)

Rep-triggered email is email sent by individual sales representatives from within Veeva CRM. The rep selects an approved email fragment or template, optionally personalizes it (within approved parameters), and sends it to specific HCPs in their territory. The email appears to come from the rep's name and email address, creating a personal touchpoint that reflects the existing rep-HCP relationship.

Key characteristics:

• Decentralized execution by individual sales representatives
• Content is pre-approved through MLR, but the rep selects which fragments to include
• Recipients are selected by the rep based on territory knowledge and call context
• Timing is determined by the rep, often as a follow-up to a recent call or event
• Volume is limited by the number of reps and their sending activity
• Compliance relies on rep adherence to approved content guidelines

Performance Benchmarks: Approved Email vs RTE

The most common question teams ask is: which channel performs better? The answer is nuanced because performance depends on what you measure and the context of the send. Here are the key benchmarks across the pharmaceutical industry, based on 2025-2026 cross-brand data.

The data reveals a clear pattern: RTE produces significantly higher engagement rates on a per-send basis because the personal sender address and contextual relevance drive higher open and click rates. However, Approved Email generates higher total prescribing impact because it operates at 5-10x the volume. Neither channel is universally superior; the optimal strategy uses both.

When to Use Approved Email

Approved Email is the workhorse of the pharma email channel. It should be the default choice for the following use cases:

Broad Awareness and Education

When you need to reach your entire target list with a consistent message, Approved Email is the only practical option. This includes new data announcements, indication expansions, formulary updates, and disease education campaigns. The centralized control ensures every HCP receives the same MLR-reviewed content, maintaining brand consistency at scale.

Automated Nurture Sequences

Behavioral nurture sequences that respond to HCP engagement signals (opens, clicks, webinar attendance) are best executed through Approved Email because the automation logic is managed centrally. A typical nurture sequence might include 4-6 emails sent over 30-60 days, with content and timing adjusting based on whether the HCP opens and clicks each send. This level of automated personalization is not feasible through RTE because it requires real-time behavioral triggers and centralized orchestration.

HCPs Without Rep Access

A significant portion of most target lists, typically 20-40% of HCPs, have limited or no rep access. These HCPs can only be reached through non-personal channels. Approved Email is the primary email touchpoint for this population, and its performance for no-access HCPs is not significantly different from its performance for HCPs with rep access, since the channel does not depend on a personal relationship.

Time-Sensitive Communications

When you need to communicate something quickly, such as a safety update, competitive response, or event invitation, Approved Email can be deployed to the full target list within hours of MLR approval. RTE depends on individual rep action, which introduces variability in timing and coverage.

When to Use RTE

RTE is the precision instrument in the email toolkit. It should be deployed strategically for use cases where personal context and the rep relationship add measurable value.

Post-Call Follow-Up

The highest-performing RTE use case is the post-call follow-up. After a rep has a detailed conversation with an HCP, they send a follow-up email that references the specific topics discussed and provides supporting materials. This creates a reinforcing loop: the call builds clinical confidence, the email reinforces the key messages and provides materials the HCP can review at their own pace, and the combined effect drives significantly higher prescribing conversion than either channel alone.

Cross-brand analysis shows that HCPs who receive a post-call RTE within 48 hours of a rep visit are 30-40% more likely to progress to the next journey stage compared to those who receive only the rep visit. The key is the recency and relevance: the email arrives while the conversation is still fresh and provides specific materials tied to the HCP's expressed interests.

Pre-Call Engagement

Sending an RTE before a scheduled rep visit can prime the HCP for a more productive conversation. The email might preview the topic of the upcoming visit, share a clinical data snippet, or invite the HCP to review materials in advance. HCPs who receive pre-call RTEs show 20-30% higher call quality scores and longer, more engaged conversations during the subsequent rep visit.

Relationship Maintenance

For high-value HCPs who are on maintenance cadences (quarterly rep visits), RTE provides additional touchpoints between visits that keep the brand top-of-mind without requiring additional rep travel. A quarterly rep visit supplemented by monthly RTEs maintains significantly higher engagement levels than a quarterly visit alone, at a fraction of the cost of additional in-person calls.

Event Follow-Up

After an HCP attends a speaker program, webinar, or congress event, a personalized RTE from the rep provides a tailored follow-up that connects the event experience to the HCP's specific practice context. This is far more effective than a generic Approved Email follow-up because the rep can reference the specific topics the HCP showed interest in during the event.

The Decision Framework

Use this decision framework to determine which channel to deploy for each email communication:

Combining Both Channels: The Power of Sequencing

The most effective email strategy sequences Approved Email and RTE in coordinated patterns that leverage the strengths of each. Here are three proven sequencing patterns:

Pattern 1: Broad-to-Deep

Approved Email (broad awareness) → RTE (personal deepening)

Send an Approved Email to the full target list announcing new clinical data. Monitor opens and clicks. For HCPs who engaged with the email (clicked on specific efficacy data), trigger an RTE task for the assigned rep to send a follow-up with additional supporting evidence. The rep's RTE references the content the HCP already engaged with, creating a seamless escalation from awareness to clinical deepening.

Results: Brands using this pattern report 40-60% higher click-through rates on the RTE follow-up compared to RTE sent without prior Approved Email context. The initial Approved Email warms up the HCP and identifies their specific interests, making the rep's follow-up more relevant and timely.

Pattern 2: Personal-to-Broad

RTE (personal introduction) → Approved Email (sustained nurturing)

After a rep visit, the rep sends an RTE follow-up that references the conversation and provides materials. The HCP is then automatically enrolled in an Approved Email nurture sequence that builds on the topics discussed during the visit. This pattern is particularly effective for converting HCPs from "Considering Trial" to "Trial/Early Adoption" because it combines the personal trust of the rep relationship with the sustained, systematic follow-up that only automated nurturing can provide.

Pattern 3: Dual-Wave Launch

Approved Email (simultaneous) + RTE (simultaneous)

For major campaign launches (new indication, major data release), deploy both channels simultaneously but with complementary content. The Approved Email delivers the headline data to the full list with a clear, concise presentation. The RTE, sent by reps to their highest-value targets the same week, provides a more personalized framing that connects the new data to each HCP's specific clinical context. The dual wave creates both breadth (everyone sees the news) and depth (key targets get a personal interpretation).

Workflow and MLR Considerations

The compliance workflow differs significantly between the two channels, and understanding these differences is essential for planning and execution.

Approved Email MLR Workflow

Approved Email content goes through the full MLR review process before deployment. The marketing team creates the email template, submits it for Medical, Legal, and Regulatory review, makes revisions based on reviewer feedback, and receives final approval. Once approved, the template is locked and can be used for a defined period (typically 6-12 months) before it must be reviewed again. The entire MLR cycle typically takes 2-6 weeks from initial submission to final approval.

Advantage: Centralized control ensures compliance. The marketing team has full visibility into what is being sent, when, and to whom.

Challenge: The MLR cycle time can be a bottleneck for time-sensitive communications. If a competitor announces a label change and you want to respond with email, you need pre-approved content or an expedited review process.

RTE MLR Workflow

RTE content is pre-approved as modular email fragments that reps can combine and send from within Veeva CRM. Each fragment (headline, body text, clinical data callout, safety information) is individually MLR-reviewed. The rep selects which fragments to include in each email, but the content within each fragment cannot be modified. The MLR review happens once during the content creation process, and then reps can use the approved fragments indefinitely (within the approval expiration date).

Advantage: Speed and flexibility. Reps can assemble and send emails within minutes, responding to specific HCP needs in near-real-time after a call. No per-send MLR review is required.

Challenge: Compliance depends on rep adherence to guidelines. While the fragment content is pre-approved, the rep decides which fragments to combine and when to send. This creates compliance risk if a rep selects inappropriate fragment combinations or sends content that is not relevant to the HCP's clinical context. Regular compliance audits and rep training are essential.

Budget Considerations

The cost structures of the two channels differ significantly and should inform allocation decisions:

Despite the higher per-send cost, RTE often achieves a comparable or slightly lower cost per attributed NRx due to its higher engagement and conversion rates. However, Approved Email delivers higher total NRx volume due to its greater reach. The typical allocation for email-specific budget is 55-65% to Approved Email and 35-45% to RTE, though this varies by brand lifecycle stage and HCP access levels.

Measuring Combined Channel Performance

To effectively manage both email channels, track these combined-channel metrics:

• Combined email engagement score: A weighted composite of open rates, click rates, and content engagement across both channels, normalized for volume differences.
• Channel overlap rate: The percentage of HCPs who receive both Approved Email and RTE within a 30-day window. Target: 40-60% for high-value HCPs, 10-20% for mid-value HCPs, 0% for no-access HCPs.
• Sequencing effectiveness: Measure prescribing conversion for HCPs who received coordinated sequences (Approved Email followed by RTE, or vice versa) versus those who received only one channel. The difference quantifies the synergy value.
• RTE send rate: Track what percentage of target HCPs receive at least one RTE per month. Low send rates (below 30% of eligible HCPs) indicate that reps are under-utilizing the channel, often due to lack of training or unclear expectations.

The bottom line is simple: Approved Email and RTE are not competitors for your email budget. They are complementary tools that serve different purposes. Approved Email provides breadth and automation. RTE provides depth and personalization. The brands that achieve the best email channel performance invest in both, coordinate them strategically, and measure the combined impact rather than treating them as isolated channels.